Compassionate Use or Expanded Access of Dupilumab

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT04776694
Status
Available

Conditions

  • Type 2 Inflammatory Disorders

Eligibility Criteria

Sex
ALL
Age
6 Months - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — DRUG
    To be provided by Regeneron

Study Details

Provide Compassionate Use or Expanded Access of Dupilumab

Key Dates

First listed
Mar 2, 2021
Status verified
Aug 2026

Central Contacts

  • Requests must be initiated by a treating physician. Physicians should contact
    844-734-6643
    [email protected]